ngµç×ÓÓÎÏ·

05

¿ÆÑÐÏ£Íû

Á¥ÊôµÚÈýҽԺ½ÕýÆë½ÌÊÚÍŶÓÁªºÏÖÐɽҽѧԺÏîÅô½ÌÊÚÍŶÓÕ¹ÏÖ¼ä³äÖʸÉϸ°û¼õÇá×äÖкóÃâÒßÒÖÖÆ×ÛºÏÕ÷»úÖÆ

¸å¼þȪԴ£º£º£ºÁ¥ÊôµÚÈýÒ½Ôº ÔĶÁÁ¿£º£º£º

¿ËÈÕ£¬£¬ngµç×ÓÓÎÏ·Á¥ÊôµÚÈýÒ½ÔºÄÔ²¡ÖÐÐĽÕýÆë½ÌÊÚÍŶÓÁªºÏÖÐɽҽѧԺÏîÅô½ÌÊÚÍŶÓÔÚ×ÔÈ»×Ó¿¯ÉúÎïҽѧ1ÇøÔÓÖ¾Signal Transduction and Targeted Therapy£¨IF£º£º£º13.493£©ÉϽÒÏþÂÛÎÄ£¬£¬Õ¹ÏÖ¾²ÂöÒÆÖ²¹ÇËèȪԴµÄMSC¿ÉÓÐÓûº½â´óÄÔÖж¯Âö˨Èû£¨middlearteryocclusion£¬£¬MCAO£©µÄAISÄ£×ÓСÊó×äÖкóÆ¢ÔàήËõµÄÃâÒßÒÖÖÆ×´Ì¬£¬£¬½µµÍÁË×äÖÐÊóµÄ·Î²¿¼°ÍâÖÜѪµÄϸ¾úÔØÁ¿¼°éæÃüÂÊ£¬£¬ÎªÖÎÁÆ×äÖкóÃâÒßÒÖÖÆ×ÛºÏÕ÷ºÍ×äÖкóѬȾÌṩÁËÐÂµÄÆ«Ïò¡£¡£¡£ngµç×ÓÓÎÏ·ÖÐɽҽѧԺÏîÅô½ÌÊÚ£¬£¬Á¥ÊôµÚÈýҽԺ½ÕýÆë½ÌÊÚ¡¢¡¢¡¢Çñΰ½ÌÊÚΪÎÄÕÂÅäºÏͨѶ×÷Õߣ»¿ÎÌâ×é³ÉÔ±Á¥ÊôµÚÈýÒ½ÔºÉñ¾­ÄÚ¿Æ»ÆÒ»Å¨²©Ê¿¡¢¡¢¡¢Á¥ÊôµÚÆßÒ½ÔºÌØÆ¸Ñо¿Ô±Íô½¨³É²©Ê¿ÎªÎÄÕÂÅäºÏµÚÒ»×÷Õß¡£¡£¡£

×äÖкóѬȾ£¨post-strokeinfection£¬£¬PSI£©Êǵ¼Ö¼±ÐÔȱѪÐÔ×äÖУ¨acuteischemicstroke£¬£¬AIS£©»¼ÕßéæÃüµÄÖ÷ÒªÔ­Òò¡£¡£¡£×äÖкóÃâÒßÒÖÖÆ×ÛºÏÕ÷£¨stroke-induced immunodepression syndrome (SIDS)£©Êǵ¼ÖÂ×äÖкóѬȾºÍéæÃüµÄ×ï¿ý×ï¿ý¡£¡£¡£Òò´Ë£¬£¬×·ÇóÓÐÓÃÖÎÁÆSIDSÆÈÔÚü½Þ¡£¡£¡£

½üÄêÀ´£¬£¬·¢Ã÷SIDS»¼Õ߯ձ鱣´æÆ¢ÔàήËõ¡£¡£¡£¶ø¹ÇËèȪԴµÄ¼ä³äÖʸÉϸ°û£¨bone marrow mesenchymal stromal cells£¬£¬BM-MSCs£©Òò¾ßÓÐǿʢµÄ×éÖ¯ÐÞ¸´¼°ÃâÒßµ÷Àí¹¦Ð§£¬£¬ÓÐÍûͨ¹ýµ÷Àí»úÌåÃâÒßÎÈ̬ÖÎÁÆPSI¡£¡£¡£

Ñо¿Ö°Ô±·¢Ã÷¾²ÂöÒÆÖ²µÄBMSCÖ÷Òª¶¨Ö²ÔÚÆ¢Ôà±ßÑØÇø£¨MZ£©£¬£¬Í¨¹ýת´ï¹¦Ð§Õý³£µÄÏßÁ£Ì嵽ƢÔà±ßÑØÇøBϸ°û£¬£¬±£»¤ÁËÕâһȺ¾ßÓйÌÓÐÃâÒßÌØÕ÷ºÍ¿¹Ñ¬È¾¹¦Ð§µÄÆ¢ÔàÁܰÍϸ°û£¬£¬´Ó¶ø½µµÍÁ˷β¿Ñ¬È¾ÂÊ¡£¡£¡£

Ê×Ò³|ngµç×ÓÓÎÏ·Öйú¼¯ÍŹٷ½ÍøÕ¾

MSCͨ¹ý±£»¤MZBϸ°ûʩչ¿¹Ñ¬È¾¹¦Ð§

Óë¼ÈÍùһЩ¾²ÂöÒÆÖ²¸Éϸ°ûÑо¿Ò»ÖµÄÊÇ£¬£¬Ñо¿Õß·¢Ã÷¾²ÂöÒÆÖ²µÄMSC´ó×Ú»üÁôÔÚÆ¢Ô࣬£¬½öÉÙÁ¿Ï¸°ûµÖ´ïËðÉ˲¡Ôî¡£¡£¡£¶ø±¾ÎÄ×÷Õß½øÒ»²½ÏêϸÆÊÎöÁ˶¨Ö²ÔÚÆ¢ÔàµÄMSCͬÑù¾ßÓÐÏìÓ¦µÄÖÎÁÆ×÷Ó㬣¬´Óµ÷ÀíÆ¢ÔàÍâÖÜÃâÒߵĽǶÈ£¬£¬ÎªÖÎÁÆPSIÌṩÁËеÄ˼Ð÷¡£¡£¡£

ÂÛÎÄÁ´½Ó£º£º£ºhttps://www.nature.com/articles/s41392-020-00415-0

¡¾ÍøÕ¾µØÍ¼¡¿